Article Text

PDF
Original research
Prasugrel is effective and safe for neurointerventional procedures
  1. William R Stetler1,
  2. Neeraj Chaudhary2,
  3. Byron Gregory Thompson1,
  4. Joseph J Gemmete2,
  5. Cormac O Maher1,
  6. Aditya S Pandey1
  1. 1Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA
  2. 2Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
  1. Correspondence to Dr A S Pandey, Department of Neurosurgery, University of Michigan Health System, 1500 E Medical Center Drive, Room 3552 Taubman Center, Ann Arbor, MI 48109-5338, USA; adityap{at}med.umich.edu

Abstract

Background Clopidogrel bisulfate and aspirin are routinely administered as dual antiplatelet agents for many neurointerventional procedures, especially for intravascular stent placement. Many patients are non-responsive to clopidogrel, either secondary to drug interactions or from variations of cytochrome P450 enzymes. Prasugrel (brand name Effient, Eli Lilly and Company, Indianapolis, IN, USA) is a new antiplatelet agent that has been utilized extensively in patients undergoing cardiovascular procedures but its safety and efficacy during neurointerventional procedures have not been evaluated.

Objective To examine whether prasugrel is a safe and effective alternative to clopidogrel for neurointerventional procedures, especially in those patients who are either non-responders or allergic to clopidogrel.

Methods The medical records of all patients undergoing neurointerventional procedures at our institution who received prasugrel between January 2009 and July 2011 were retrospectively reviewed. A systematic chart review was performed and the following data were recorded: demographics, aneurysm location, endovascular techniques, peri- and post-procedural complications, hemorrhagic complications, clinical outcome and angiographic outcome.

Results 16 patients undergoing neurointerventional procedures received prasugrel over a 2 year interval. All patients who had follow-up studies of P2Y12 inhibition had immediate therapeutic response to prasugrel. There were no complications related to ischemic or intracranial hemorrhage.

Conclusion Prasugrel is a viable alternative to clopidogrel for patients undergoing neurointerventional procedures who are non-responders to clopidogrel. Further study is needed to evaluate the safety, efficacy and cost-effectiveness of prasugrel compared with clopidogrel for patients undergoing neurointerventional procedures.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the University of Michigan Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles